Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Also, if it's the last quarter results that are public, why would this not be relevant might I ask? It's pretty standard in the industry for the last posted quarter results to stay relevant untill the next quarter or year end becomes publicly available. Do you know something the market does not on why the most recent c.c. would not be relevant??
Just wondering because the fact you question this would make one think you are fairly new to the investing world, which is fine, but I like to know where you're coming from that's all 🤔🤔🤔
I have a hard time cheering someone who posts 4 month old info without a qualifier that it is 4 month old information. Couple that with your sudden appearance and flip from bearish to bullish within 3 weeks of each other....
I posted this because it was the last earnings on record. Q3 2023 results are a good indicator of growth and ramp for BLUE. The next c.c. is only weeks away for full year 2023 and fourth quarter 2023 which are normally combined into 1 earnings report and c.c.
Cheers
Nov 7, 2023 at 8:00 AM EST has long since passed.
Why did you post this?
One of the top 25 Bio companies of 2024.
https://thehealthcaretechnologyreport.com/the-top-25-biotechnology-companies-of-2024/
BLUE..................................................https://stockcharts.com/h-sc/ui?s=BLUE&p=W&b=5&g=0&id=p86431144783
FDA Ramrod x2, + shorts.
Honestly -- what happened to this company?
I have never actually invested in BLUE but I have been following it for a while. I live near by and know some people who work for them. From what they could talk about and the press releases and journal articles i've read, it seems like they have an amazing technology that works to find solutions (cures) to unique problems. How did they go from trading over 200+ a share to this?
That would be lovely, but what's your info?
At 190.4mm shares to 20 per, that's 3.8 Billion - or over 1000 drug sales at 2.75m avg. BLUE forecasted 80-100 sales this year.
Buyout is in the works. Very short time will be made public. Anything below $20.00 vote no. 3 blockbusters here
BLUE.......................................https://stockcharts.com/h-sc/ui?s=BLUE&p=W&b=5&g=0&id=p86431144783
I believe the bottom has come and gone. I wouldn't expect to see anything below $0.95 again.
On average, Wall Street analysts predict that Bluebird Bio's share price could reach $6.87 by Dec 21, 2024. The average Bluebird Bio stock price prediction forecasts a potential upside of 566.8% from the current BLUE share price of $1.03.
This guy wants your shares of BLUE ruhl bad, me thinks.
Bottom is far from in. Amrn hit .65 cents just a few months ago. Sadly, blue won't recover imho
Amrn dropped to .65 cents before making any recovery. Unfortunately, this is not bottom for bluebird bio
Reverse split inevitable here. Too many shares on the market now thanks to recent share sales. Float reduction is needed to move this bloated pig anywhere now unfortunately and that's why it continues below $1.00. Amrn hit .65 cents before it's bounce so prepare yourself this isn't even close to bottom
I seen this Bio and did little DD. But in the few minutes, one thing stood out. It causes cancer. You guys that did more DD might know something or see something that gives you confidence to invest here. I pass. Good luck guys.
I seen this Bio and did little DD. But in the few minutes, one thing stood out. It causes cancer. You guys that did more DD might know something or see something that gives you confidence to invest here. I pass. Good luck guys.
Ask, and you shall receive! Lol
Item 7.01
Regulation FD Disclosure.
bluebird bio, Inc. (the "Company") has signed a second outcomes-based agreement for LYFGENIA, bringing the cumulative total of covered lives for LYFGENIA to approximately 200 million, less than one month since FDA approval of LYFGENIA on December 8, 2023 for sickle cell disease in patients 12 and older with a history of vaso-occlusive events. Additional updates on the commercial launch of LYFGENIA will be presented at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.
Let’s see if we get any updated guidance ( Rev’s, cash burn, PRV dispute, Payers, etc)…biggest Conf on earth, LFG!!!
bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 10:30am PT/1:30pm ET.
What's that about BLUE?
"In connection with the approval of LYFGENIA, we did not receive a Rare Pediatric Disease Priority Review Voucher that we requested as part of the FDA’s review. We are evaluating the FDA’s denial and plan to dispute this decision with the FDA."
https://ih.advfn.com/stock-market/NASDAQ/bluebird-bio-BLUE/stock-news/92864211/form-424b5-prospectus-rule-424b5
That's one interpretation, for sure.
There should have been an adcom meeting. This has been one hell of a hit job by the FDA, from the scheduling and early announcement for Lyfgenia, all the way back to the fall of '21.
IMO, the FTC should be examining anti-trust action against the FDA.
What this pricing says, is that Goldman/JPM could NOT get their clients interested unless a 50% haircut from the Closing price ($3ish) beginning of week!! Brutal!! But bought some now @ $1.40preM and will step in post open!
I understand giving a discount to sell shares, but 40% is quite steep.
Things like that keep people away from the market.
After getting burned a couple of times in bio, I basically refuse to hold overnight.
I trade to generate an income and the possibility of a 40% haircut is real.
Crap like this dissuades people from getting involved.
And if you get stung, you can't trade for a few days/weeks as you try to force back to even. (Revenge trading)
bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today announced the pricing of its underwritten public offering of 83,333,333 shares of its common stock at a public offering price of $1.50 per share, before deducting underwriting discounts and commissions. bluebird also granted the underwriters a 30-day option to purchase up to an additional 12,499,999 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds from the public offering are expected be $125 million, before deducting underwriting discounts and commissions and offering expenses payable by bluebird and assuming no exercise of the underwriters' option to purchase additional shares of common stock. All shares in the offering are to be sold by bluebird.
Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as joint book running managers for the offering. Raymond James & Associates, Inc. is acting as co-manager for the offering.
bluebird intends to use the net proceeds of the offering (i) to support commercialization and manufacturing for its three approved gene therapies, ZYNTEGLO, SKYSONA and LYFGENIA; and (ii) to fund working capital and other general corporate purposes.
The offering is expected to close on or about December 22, 2023, subject to customary closing conditions.
The
Giddy Up! Let the fireworks begin:
bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. bluebird also intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of its common stock to be sold in the offering. The offering, actual size and terms are subject to market conditions, and there can be no assurance as to whether or when the offering may be completed. All shares in the offering are to be sold by bluebird.
Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as joint book running managers for the offering. Raymond James & Associates, Inc. is acting as co-manager for the offering.
Oh, of course.
It'll moon out someday, I'm not worried about any of that.
Let’s just be ready for the next positive PR, and bump in SP , followed by rai$e( which btw isn’t a total bummer, and we have all seen this event be short lived dilution) BUT if a ‘tight’ Syndicate, a parabolic rally post close:) GLTA
8k out
"Following the FDA approval of LYFGENIA on December 8, 2023 for sickle cell disease in patients 12 and older with a history of vaso-occlusive
events, bluebird bio, Inc. (the “Company”) has signed an outcomes-based agreement with an organization representing approximately 100 million covered
lives in the U.S. Additionally, the Company is in advanced discussions with a number of the nation’s other large commercial payers and more than 15
Medicaid agencies collectively representing 80% of individuals with sickle cell disease in the U.S. The Company anticipates 85 to 105 patient starts (cell
collections) combined across all three of its commercial products (LYFGENIA, ZYNTEGLO, SKYSONA) in 2024."
https://investor.bluebirdbio.com/static-files/a9da7005-b393-4e1b-bf28-71850b6a47a8
80% is ...wow.
"several more to go"
Say what?
One down, several more to go!
Item 7.01
Regulation FD Disclosure.
Following the FDA approval of LYFGENIA on December 8, 2023 for sickle cell disease in patients 12 and older with a history of vaso-occlusive events, bluebird bio, Inc. (the “Company”) has signed an outcomes-based agreement with an organization representing approximately 100 million covered lives in the U.S. Additionally, the Company is in advanced discussions with a number of the nation’s other large commercial payers and more than 15 Medicaid agencies collectively representing 80% of individuals with sickle cell disease in the U.S. The Company anticipates 85 to 105 patient starts (cell collections) combined across all three of its commercial products (LYFGENIA, ZYNTEGLO, SKYSONA) in 2024.
Bluebird Bio Said Anticipates 85 To 105 Patient Starts Combined Across All Three Of Its Commercial Products In 2024…
Thanks, guess that's it then about the PRV. Disappointing for sure,but BLUE will do okay even without. Let's hope there will be breakthroughs on the Insurance cover or treatment pricing.
Spot on Moose, no PRV because of same ‘active ingredient’…I received a message from a Highly Respected poster and he replied back to my same question:
DewDiligence
Member Level
Re: stocksrising post# 250000
Saturday, 12/09/2023 5:38:10 PM
BLUE didn’t get a priority-review voucher for FDA approval of Lyfgenia because the FDA deemed that the “active ingredient” in Lyfgenia is the same as in BLUE’s Zynteglo, which was approved in 2022 for beta thalassemia (#msg-169711368).
This is a seemingly odd interpretation by the FDA of the term, “active ingredient,” but the FDA is given broad discretion by the legal system in these kinds of decisions
This is the best I can find:
"The FDA issued a rare disease priory review voucher (PRV) accompanying the approval for Casgevy but not for Lyfgenia. Companies can use these vouchers to expedite FDA’s review of other drugs.
Analysts at Cantor suspected that because bluebird already got a PRV on Zynteglo, which is a twin therapy to Lyfgenia, the FDA may have viewed the request for a new PRV as double-dipping."
https://www.fiercepharma.com/pharma/fda-approves-bluebird-sickle-cell-disease-gene-therapy-can-lyfgenia-overcome-crisprs-halo
Do we know if the PRV been actually declined for BLUE? Or is it simply being assumed that it's not happening since there's been no confirmation on it?
I would be thrilled w a $10/sh buyout. I believe BLUE is worth far more, but nonetheless.
There will likely be several Class Action ambulance chasers, but Blue has made it clear on/in several PR’s that it’s NOT 💯 until FDA says so!
“Closing of the transaction remains subject to the approval of lovo-cel and receipt of a PRV from the FDA, as well as customary closing conditions”.
Sucks for US because of near term dilution about to hit!!
Wouldn’t be surprised if major Pharma Co. Buys them out ??? $10ish X’s 110mm shrs out = $1b+ EV
3 approved drugs generating $250-500mm in revs over next couple years discounted back plus other potential indications with their IP technology??
Total guess, but nothing surprises anymore! :)
Followers
|
53
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
508
|
Created
|
09/05/13
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |